|
ZNF343 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.25280008589357E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.23760002246343E-10 |
| Normal-vs-Stage2 |
1.74689999998812E-06 |
| Normal-vs-Stage3 |
1.03320019206876E-10 |
| Normal-vs-Stage4 |
3.91669996435695E-09 |
| Stage1-vs-Stage2 |
4.633600E-02 |
| Stage1-vs-Stage3 |
5.129800E-01 |
| Stage1-vs-Stage4 |
6.838400E-01 |
| Stage2-vs-Stage3 |
3.743500E-02 |
| Stage2-vs-Stage4 |
7.923700E-02 |
| Stage3-vs-Stage4 |
9.385200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.56490442405311E-11 |
| Normal-vs-AfricanAmerican |
1.366820E-04 |
| Normal-vs-Asian |
4.21370000003307E-08 |
| Caucasian-vs-AfricanAmerican |
3.060600E-01 |
| Caucasian-vs-Asian |
1.610750E-01 |
| AfricanAmerican-vs-Asian |
8.691000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.55069998456037E-09 |
| Normal-vs-Female |
6.83799683542929E-11 |
| Male-vs-Female |
2.498400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.38089581173062E-11 |
| Normal-vs-Age(41-60Yrs) |
3.15840020803648E-10 |
| Normal-vs-Age(61-80Yrs) |
1.47379997095243E-09 |
| Normal-vs-Age(81-100Yrs) |
2.88630000011558E-07 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.788600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.533200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.679800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.206800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.827400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.321700E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.25760000000164E-06 |
| Classical-VS-Follicular |
1.591030E-01 |
| Classical-VS-Other |
6.120800E-01 |
| Classical-VS-Normal |
5.16499998326481E-09 |
| Tall-VS-Follicular |
7.017800E-03 |
| Tall-VS-Other |
1.678600E-01 |
| Tall-VS-Normal |
1.79234405095485E-12 |
| Follicular-VS-Other |
4.440200E-01 |
| Follicular-VS-Normal |
8.63770055481439E-10 |
| Other-VS-Normal |
6.782100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.15690029673021E-10 |
| Normal-vs-N1 |
2.20679996498774E-09 |
| N0-vs-N1 |
3.991600E-01 |
|
|
